Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending1
- Paying for drugs in Medicare Part D under current law and under proposals to redesign the program1
- Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates1
- Prescription drugs and Medicare Part D: a report on access, satisfaction, and cost1
- Prescription drugs in Nebraska: a survey of experiences and opinions1
- Prescription drugs: spending, use, and prices1
- Reducing potential overuse of dementia drugs could lead to considerable savings1
- Report on the affordability of insulin1
- Searching for savings in Medicare drug price negotiations1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- State biosimilar substitution laws could reduce consumer access and savings1
- Strategic analysis & intelligence (SAI) report: the tier 4 phenomenon : shifting the high cost of drugs to consumers1
- Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs1
- The Medicaid Drug Rebate Program: the basics1
- The Pharmaceutical Industry Must Join America1
- The effect of Medicare Part D on evergreening, generic entry, and drug prices1
- The rising cost of specialty drugs drove spending increases for people with multiple sclerosis1
- What can the United States learn from pharmaceutical spending controls in France?1
- What's the latest on Medicare drug price negotiations?1
- What’s the latest on Medicare drug price negotiations?1